Fagron

Fagron is a multinational healthcare company focused on pharmaceutical compounding, the preparation of medicines tailored to the needs of individual patients. Its products and services support pharmacists, hospitals, and other healthcare institutions that prepare customized formulations when a commercially manufactured medicine does not provide an appropriate dosage, strength, dosage form, ingredient profile, or route of administration. The company’s activities are rooted in the traditional compounding role of the pharmacy, represented by the mortar and pestle, but are organized as an international business serving professional healthcare customers. The business was established in Rotterdam in 1990 by Ger van Jeveren as a distributor of pharmaceutical raw materials. Omega Pharma acquired Fagron in 2000 as part of a broader buy-and-build strategy involving specialist healthcare companies. In 2006, Omega Pharma created Arseus as an umbrella organization for its professional healthcare division. Arseus brought together approximately 35 smaller businesses and included Fagron alongside dental, medical-distribution, and healthcare-software activities. Arseus became an independent publicly traded company through an initial public offering on October 5, 2007. Its shares were listed on Euronext Brussels and Euronext Amsterdam, while Omega Pharma initially retained a minority holding. In 2009, Omega Pharma sold its remaining stake to the private-equity investor Waterland; Marc Coucke retained a smaller indirect interest through Couckinvest. The company later reorganized its divisions and progressively narrowed its portfolio. During the 2012 restructuring, Arseus discontinued the separate Arseus Dental and Arseus Medical divisions and replaced them with Healthcare Solutions and Healthcare Specialities. Those activities combined dental and medical distribution with the development and marketing of related products. In 2014, the majority of both healthcare divisions was sold after a period of underperformance. Arseus retained Fagron and Corilus and added HL Technology, a smaller unit involved in equipment for dental and orthopedic applications. Fagron’s core activity is the supply of ingredients, dosage forms, equipment, and related know-how used in compounding. Its customer base includes pharmacies and hospitals, and its products are sold internationally through operations in Europe, the Americas, and other regions. The company has also operated through national subsidiaries and local businesses, including activities in Poland, Brazil, and Argentina. In the reference period described by the available material, Fagron reported customers in more than 55 countries and operations in 29 countries. The Fagron brand is therefore positioned less as a consumer-facing medicine brand than as a professional healthcare platform. Its value proposition centers on helping healthcare professionals deliver individualized medication and nutrition solutions, supported by specialized raw materials, formulations, and services. The available reference material identifies Rafael Padila as chief executive of the Fagron Group, but does not provide a reliable current leadership date or a detailed account of the company’s latest operations. Financial and ownership information beyond the historical figures and transactions described below is not included because a sufficiently specific current source is unavailable.

Fagron originated in Rotterdam in 1990, when Ger van Jeveren established a business distributing raw materials for medicines. Its founding activity was closely connected with pharmaceutical compounding: the preparation of medicines adjusted to the requirements of particular patients. Compounding can be used when a patient needs a strength or dosage form that is not commercially available, or when an ingredient in a standard product causes an allergy or is otherwise unsuitable. In 2000, Omega Pharma acquired Fagron as part of its long-running strategy of purchasing and developing specialized healthcare companies. Omega Pharma subsequently created Arseus in 2006 to serve as an umbrella organization for its professional healthcare division. Arseus integrated roughly 35 smaller businesses, including Fagron, dental and medical suppliers, and healthcare-software operations. The first available Arseus annual report was published in 2007. Arseus became independent through an initial public offering on October 5, 2007. The company was listed on Euronext Brussels and Euronext Amsterdam, and Omega Pharma initially retained 24 percent of its shares. In November 2009, Omega Pharma sold that holding to Waterland, a private-equity investor. Marc Coucke continued to hold an interest through Couckinvest, later reducing his stake in 2014. Arseus reorganized its operating structure in 2012. The former Arseus Dental and Arseus Medical divisions were replaced by Healthcare Solutions, which combined dental and medical distribution, and Healthcare Specialities, which grouped businesses developing and marketing new dental and medical products. Fagron and Corilus continued as distinct businesses within the group. In 2014, Arseus sold the majority of Healthcare Solutions and Healthcare Specialities. These divisions had underperformed for some time, and the disposals reduced the group’s exposure to those activities. Arseus retained Fagron and Corilus and added HL Technology, a smaller division involved in the development and manufacture of equipment for dental and orthopedic applications. Fagron remained the group’s specialist pharmaceutical-compounding business. The company’s international activities have included Europe, the United States, Brazil, Argentina, and additional markets in Africa, Asia, and the Pacific. The available reference material describes Fagron products as being sold to customers in more than 55 countries and states that the group operated in 29 countries during the period covered by that material. Its professional customers include pharmacists, hospitals, and other healthcare institutions. The company’s historical business scope also included nutritional and cosmetic solutions, although the available material identifies pharmaceutical compounding as the central activity. Fagron is governed under Belgian law, has its registered office in Waregem, Belgium, and maintains its headquarters in Rotterdam in the Netherlands. Its shares have been described as included in the BEL MID index and the Amsterdam Small Cap Index. The supplied sources do not provide sufficient current information to document later ownership changes, recent financial performance, or the complete present-day executive structure.

1. 2014Healthcare division disposals

   The majority of Healthcare Solutions and Healthcare Specialities was sold, leaving Fagron and Corilus as continuing core businesses and adding HL Technology.

   Source
2. 2012Divisional restructuring

   Arseus replaced its separate dental and medical divisions with Healthcare Solutions and Healthcare Specialities.

   Source
3. 2009Omega Pharma exits Arseus

   Omega Pharma sold its remaining stake in Arseus to Waterland.

   Source
4. 2007Arseus initial public offering

   Arseus became an independent listed company through an IPO on October 5 and began trading on Euronext Brussels and Euronext Amsterdam.

   Source
5. 2006Arseus established

   Omega Pharma formed Arseus as an umbrella group for its professional healthcare division, including Fagron.

   Source
6. 2000Acquisition by Omega Pharma

   Omega Pharma acquired Fagron as part of its buy-and-build expansion across specialized healthcare businesses.

   Source
7. 1990Fagron founded in Rotterdam

   Ger van Jeveren founded Fagron as a distributor of pharmaceutical raw materials.

   Source

A professional healthcare supplier and international specialist in pharmaceutical compounding, helping pharmacies and hospitals prepare patient-specific medicines and related nutritional solutions.

• Fagron compounding ingredientsPharmaceutical compounding

  Raw materials and related ingredients supplied to pharmacists and hospitals for the preparation of patient-specific medicines. These materials support formulations that may require a different strength, dosage form, or ingredient profile from commercially manufactured products.

• Customized medicationsCompounded pharmaceuticals

  Tailor-made medication solutions prepared through pharmaceutical compounding. The business model supports individualized treatment when a standard marketed product is unsuitable or unavailable in the required form or strength.

• Nutritional productsHealthcare nutrition

  Nutrition-related products supplied as part of Fagron’s broader professional healthcare portfolio. The available reference material identifies nutrition as one of the company’s areas but does not specify individual product names or formulations.

• Cosmetic compounding productsProfessional cosmetics

  Cosmetic-related products and solutions associated with the company’s customized healthcare offering. The supplied sources mention cosmetics as part of Fagron’s scope but do not provide enough detail to identify specific ranges.

• 2014Sale of most Healthcare Solutions and Healthcare Specialities activitiesM&A

  The two divisions had reportedly underperformed for an extended period.

  What changed. Arseus sold the majority of both divisions, retained Fagron and Corilus, and added HL Technology to its continuing portfolio.

  Aftermath. The group became more concentrated in its remaining professional healthcare and technology activities.

  Source
• 2012Operating-division restructuringStrategy

  Arseus revised its divisional organization to consolidate related dental and medical activities.

  What changed. The company replaced Arseus Dental and Arseus Medical with Healthcare Solutions and Healthcare Specialities, while retaining Fagron and Corilus as separate divisions.

  Aftermath. The reorganization preceded the later sale of most Healthcare Solutions and Healthcare Specialities activities.

  Source
• 2007Arseus initial public offeringM&A

  The professional healthcare division was separated from Omega Pharma’s direct ownership structure.

  What changed. Arseus completed an IPO on October 5 and listed its shares on Euronext Brussels and Euronext Amsterdam.

  Aftermath. Omega Pharma initially retained a minority stake before selling it to Waterland in 2009.

  Source
• 2006Creation of the Arseus professional healthcare groupStrategy

  Omega Pharma had accumulated specialist healthcare companies through acquisitions and sought to organize its professional healthcare activities under a separate umbrella.

  What changed. It established Arseus and grouped approximately 35 businesses, including Fagron, into the new organization.

  Aftermath. Arseus subsequently became an independent listed company and later reorganized its portfolio around fewer operating units.

  Source

1. Fagron